Sosei Heptares Bags Second GPCR Targets Deal In A Month, With Takeda

The Japanese biotech agreed a multi-year, multi-target research collaboration and license deal with Takeda to discover and develop medicines that modulate GPCR targets, initially in GI.

Digestive_System
Their alliance will first focus on gastrointestinal targets • Source: Shutterstock

Sosei Heptares has entered a strategic multi-target partnership with Takeda Pharmaceutical Co. Ltd. to discover, develop and commercialize novel molecules, including small molecules and biologics, that modulate G protein-coupled receptor (GPCR) targets within the realm of gastrointestinal disease, but the pact could potentially expand into other therapeutic areas, Malcolm Weir, the Japanese biotech’s head of R&D, told Scrip.

Under their deal, announced on 5 August, Sosei Heptares will get up to $26m in upfront and near-term payments, and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip